Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of BI 3009947 in Healthy Male Participants
NCT07250048Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 3009947 (16 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator at Day 14, Area under the concentration-time curve from 0 to 24 hours and 1 more. Started Nov 2025; status: terminated.
02
Drugs
BI 3009947
Beyond the preview
Go deeper on NCT07250048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07250048.